Ultragenyx Pharmaceutical | RARE - Trade Debtors


Ultragenyx Pharmaceutical reported $112.54M in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 10.58M 5.55M Dec/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Immunic USD 1.5M 50K Jun/2024
Insmed USD 140.86M 75.6M Dec/2025
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Kyowa Hakko Kirin JPY 181.2B 29.38B Dec/2025
MacroGenics USD 13.37M 55.86M Dec/2025
Moderna USD 184M 862M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025
Xoma USD 14.78M 4.96M Jun/2024